Log In

 

Company Name : Philip Morris International

Thursday, December 14, 2017 9:30AM IST (4:00AM GMT)

(BW)(NY-PHILIP-MORRIS-INTL)

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program


An In-Depth Look at How Good Clinical Practices Ensure Ethical Conduct of High Quality Research and the Safety of Study Subjects


Lausanne, Switzerland

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link.

 

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/

 

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Pr ...

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire)

This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s commitment to the implementation of best practices, transparent research and the well-being of clinical trial participants.

 

Picavet stated, “The performance of clinical studies is a complicated process. Strict implementation of Good Clinical Practices is particularly important to assure the quality and consistency of the research and to address unexpected events that can occur during a study. These Practices are key to the validity of data and the safety of study participants.”

 

Beyond recent events and publications, this issue also describes PMI’s progress towards sharing all raw data from studies on IQOS in part through the new data-sharing platform called INTERVALS.

 

Prof. Manuel Peitsch, PMI’s Chief Scientific Officer, elaborates: “PMI is committed to openly sharing the research behind our smoke-free products. That’s why we are using our latest Scientific Update to explain the rigor behind our clinical program. We are going further by gradually making the data and results from the non-clinical and clinical program around our leading smoke-free product, IQOS, available to the public by early 2018.”

 

PMI’s extensive research and assessment program is inspired by the well-recognized practices of the pharmaceutical industry and in line with the draft guidance of the U.S. FDA for Modified Risk Tobacco Product (MRTP) Applications. PMI employs over 400 world-class scientists, engineers and experts who conduct rigorous research, including laboratory and clinical studies, as well as ground-breaking systems toxicology. The assessment program also includes studies on actual product use and correct understanding of product communications, as well as post-market research.

 

About Philip Morris International Inc. (“PMI”)

 

Philip Morris International Inc. (PMI) is a leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of reduced-risk products (RRPs). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see our PMI and PMI Science websites.

 

 

 

 
MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20171212005891/en/


Click here for Media Contact Details
CONTACTS :

Media enquiries
Philip Morris International media office
T: +41 (0)58 242 4500
E: media@pmi.com


More News from Philip Morris International

19/01/2019 5:21PM

PMI’s Mission Winnow Goes Full Throttle with Ducati Corse for 2019 MotoGP™

Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce that its Mission Winnow initiative is expanding in 2019 to include the Ducati Corse racing team.   Mission Winnow is a PMI-led campaign ...

19/11/2018 10:26AM

Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke

Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021.   The two ...

23/10/2018 11:30AM

Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product

In its passion and drive to provide better choices to people who smoke, Philip Morris International Inc. (“PMI”) (NYSE: PM), the global leader in smoke-free innovation and science, has launched the next ...

Similar News

21/01/2019 9:20PM

Metabolon Appoints Michael Rasche as President of International Business

Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and ...

No Image

21/01/2019 7:10PM

Bajaj Finserv Launches Republic Day Sale - Offers Attractive Cashback

Bajaj Finserv, through its digital subsidiary Bajaj Finserv Direct Ltd, announced the launch of its Republic Day Sale, offering an incredible cashback up to Rs. 2019 on every qualified purchase on its online EMI store.